JP2012520321A5 - - Google Patents

Download PDF

Info

Publication number
JP2012520321A5
JP2012520321A5 JP2011554220A JP2011554220A JP2012520321A5 JP 2012520321 A5 JP2012520321 A5 JP 2012520321A5 JP 2011554220 A JP2011554220 A JP 2011554220A JP 2011554220 A JP2011554220 A JP 2011554220A JP 2012520321 A5 JP2012520321 A5 JP 2012520321A5
Authority
JP
Japan
Prior art keywords
effective amount
therapeutically effective
difluoro
pharmaceutical composition
iodophenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011554220A
Other languages
English (en)
Japanese (ja)
Other versions
JP5767122B2 (ja
JP2012520321A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/027060 external-priority patent/WO2010105110A1/en
Publication of JP2012520321A publication Critical patent/JP2012520321A/ja
Publication of JP2012520321A5 publication Critical patent/JP2012520321A5/ja
Application granted granted Critical
Publication of JP5767122B2 publication Critical patent/JP5767122B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011554220A 2009-03-11 2010-03-11 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬 Expired - Fee Related JP5767122B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15940309P 2009-03-11 2009-03-11
US61/159,403 2009-03-11
PCT/US2010/027060 WO2010105110A1 (en) 2009-03-11 2010-03-11 Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014180216A Division JP5911929B2 (ja) 2009-03-11 2014-09-04 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬

Publications (3)

Publication Number Publication Date
JP2012520321A JP2012520321A (ja) 2012-09-06
JP2012520321A5 true JP2012520321A5 (enExample) 2013-04-04
JP5767122B2 JP5767122B2 (ja) 2015-08-19

Family

ID=42135921

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011554220A Expired - Fee Related JP5767122B2 (ja) 2009-03-11 2010-03-11 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬
JP2014180216A Expired - Fee Related JP5911929B2 (ja) 2009-03-11 2014-09-04 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014180216A Expired - Fee Related JP5911929B2 (ja) 2009-03-11 2014-09-04 特定の癌の治療のためのrdea119/bay869766を含む組み合わせ医薬

Country Status (23)

Country Link
US (2) US8673876B2 (enExample)
EP (1) EP2405908B1 (enExample)
JP (2) JP5767122B2 (enExample)
KR (1) KR20110132371A (enExample)
CN (2) CN102421427B (enExample)
AU (1) AU2010224044A1 (enExample)
BR (1) BRPI1009448A2 (enExample)
CA (2) CA2972379A1 (enExample)
CL (1) CL2011002233A1 (enExample)
CO (1) CO6430423A2 (enExample)
CR (1) CR20110479A (enExample)
CU (1) CU20110170A7 (enExample)
DO (1) DOP2011000282A (enExample)
EA (1) EA201101302A1 (enExample)
EC (1) ECSP11011314A (enExample)
HK (1) HK1199710A1 (enExample)
IL (1) IL214749A0 (enExample)
MA (1) MA33091B1 (enExample)
MX (1) MX2011009498A (enExample)
PE (1) PE20120105A1 (enExample)
SG (1) SG174272A1 (enExample)
TN (1) TN2011000455A1 (enExample)
WO (1) WO2010105110A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
NZ592338A (en) 2008-09-26 2012-11-30 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
WO2013001372A2 (en) * 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
EP2916859B1 (en) 2012-11-02 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor
US9359444B2 (en) 2013-02-04 2016-06-07 Oncomed Pharmaceuticals Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en) * 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
EP3043778B1 (en) * 2013-09-13 2017-09-06 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9925958D0 (en) * 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
US6822001B2 (en) * 2000-11-03 2004-11-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
JP2005531488A (ja) 2001-10-09 2005-10-20 ザ・ユニバーシティ・オブ・シンシナティ 甲状腺癌を処置するためのegf受容体阻害剤
US7417055B2 (en) * 2003-04-25 2008-08-26 Gilead Sciences, Inc. Kinase inhibitory phosphonate analogs
AU2005316238B2 (en) 2004-12-17 2009-05-07 Smithkline Beecham (Cork) Limited Cancer treatment method
US20060211074A1 (en) * 2005-01-12 2006-09-21 Boyce James P Kinase-directed, activity-based probes
WO2006090931A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の抗癌剤との新規併用
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
US8648116B2 (en) * 2005-07-21 2014-02-11 Ardea Biosciences, Inc. Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
US20090017050A1 (en) * 2007-07-13 2009-01-15 Ventana Medical Systems, Inc. Egfr antigen-binding molecules and uses thereof
KR20100092424A (ko) * 2007-07-30 2010-08-20 아디아 바이오사이언스즈 인크. 다형체를 포함하는, mek의 억제제로서의 n-(아릴아미노) 술폰아미드의 유도체 및 조성물, 사용 방법 및 이의 제조 방법
US8044240B2 (en) * 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
DE102008031039A1 (de) 2008-06-30 2009-12-31 Dömling, Alexander, Priv.-Doz. Dr. Tarceva zur Anwendung in der Organtransplantation.

Similar Documents

Publication Publication Date Title
JP2012520321A5 (enExample)
CN111989332A (zh) 作为cdk抑制剂的大环化合物、其制备方法及其在医药上的应用
RU2448096C2 (ru) Диарилгидантоины
JP2017530983A5 (enExample)
TW200607807A (en) Macrocyclic beta-secretase inhibitors
JP2020500862A5 (enExample)
JP2013525318A5 (enExample)
JP2019059760A5 (enExample)
JP2006523216A5 (enExample)
JP2020514316A5 (enExample)
EA201000157A1 (ru) Неосновные антагонисты рецептора меланин-концентрирующего гормона 1 типа и их применение
EA201071268A1 (ru) СПОСОБ ЛЕЧЕНИЯ РАКА С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА cMET И AXL И ИНГИБИТОРА erbB
JP2009514870A5 (enExample)
RU2017112048A (ru) Синергистические комбинации ауристана
JP2012530779A5 (enExample)
RU2013147514A (ru) Комбинации конъюгата анти-her2-антитело-лекарственное средство и химиотерапевтических средств и способы применения
MX2010005342A (es) Compuestos indola y metodos para tratar el dolor visceral.
EA200801165A1 (ru) Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона
JP2014508804A5 (enExample)
JP2011519941A5 (enExample)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
RU2428982C2 (ru) Применение соединения
EA201071006A1 (ru) Набор, композиция, продукт или лекарственное средство для лечения нарушения познавательной способности
JP2010503620A5 (enExample)
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов